|
Demographics,clinical characteristics
|
|
Age, years
|
58.0 (46.0–69.0)
|
56.0 (42.0–65.0)
|
70.0 (62.0–82.0)
|
< 0.00
|
|
Sex N (%)
| | | |
1
|
|
Male
|
189 (58%)
|
154 (57%)
|
35 (64%)
|
0.366
|
|
Female
|
136 (42%)
|
116 (43%)
|
20 (37%)
| |
|
Comorbidity N(%)
|
155 (48%)
|
117 (43%)
|
38 (69%)
|
0.001
|
|
Hypertension
|
98 (30%)
|
71 (26%)
|
27 (49%)
|
0.001
|
|
Coronary heart disease
|
31 (10%)
|
20 (7%)
|
11 (20%)
|
0.004
|
|
Chronic kidney disease
|
5 (2%)
|
2 (1%)
|
3 (6%)
|
0.036
|
|
Diabetes
|
38 (12%)
|
26 (10%)
|
12 (22%)
|
0.010
|
|
Chronic obstructive lung
|
10 (3%)
|
6 (2%)
|
4 (7%)
|
0.070
|
|
Stroke
|
16 (5%)
|
7 (3%)
|
9 (16%)
|
< 0.001
|
|
Carcinoma
|
10 (3%)
|
8 (3%)
|
2 (4%)
|
0.679
|
|
Other
|
61 (19%)
|
45 (17%)
|
16 (29%)
|
0.030
|
|
Temperature(°C),median(IQR)
|
37.0 (36.5–37.8)
|
37.0 (36.6,37.9)
|
36.6 (36.3–37.4)
|
0.014
|
|
Pulse(beats per min), median(IQR)
|
88 (80.0–97.0)
|
87.0 (80.0,96.0)
|
90.0 (80.3–99.5)
|
0.356
|
|
Respiratory rate(breaths per min), median(IQR)
|
20.0 (20.0–23.0)
|
20.0 (19.0,22.0)
|
23.0 (20.0–26.0)
|
< 0.001
|
|
Systolic blood pressure, median(IQR)
|
127.0 (117.0–138.0)
|
125.0 (115.0,138.0)
|
130.5 (127.3–146.5)
|
0.003
|
|
Diastolic blood pressure, median(IQR)
|
78.0 (70.0–85.0)
|
78.0 (70.0,85.0)
|
76.0 (65.8–85.0)
|
0.222
|
|
APACH II sore, median(IQR)
|
6.0 (4.0–9.0)
|
5.0 (3.0–7.0)
|
13.0 (9.0–29.0)
|
< 0.001
|
|
SOFA sore, median(IQR)
|
2.0 (2.0–4.0)
|
2.0 (1.0,3.0)
|
7.0 (4.0–14.0)
|
< 0.001
|
|
Clinical Classifications N (%)
| | | |
< 0.001
|
|
Severe type
|
222 (68%)
|
216 (80%)
|
6 (11%)
| |
|
Critical type
|
103 (32%)
|
54 (20%)
|
49 (89%)
| |
|
In-hospital days
|
20.0 (14.0–28.0)
|
20.0 (14.0–28.0)
|
15.0 (7.0–28.0)
|
0.003
|
|
Total course of disease a
|
28.0 (19.0–37.0)
|
27.0 (19.0–36.0)
|
30.0 (20.0–38.0)
|
0.345
|
|
Laboratory findings, median(IQR)
|
|
WBC, (1 × 109/L)
|
5.8 (4.2–8.3)
|
5.3 (4.1–7.1)
|
9.2 (5.6–15.7)
|
< 0.001
|
|
NEU,(1 × 109/L)
|
3.9 (2.6–6.5)
|
3.6 (2.4–5.4)
|
8.1 (4.8–14.4)
|
< 0.001
|
|
LYM,(1 × 109/L)
|
1.0 (0.6–1.4)
|
1.0 (0.7–1.5)
|
0.6 (0.4–0.8)
|
< 0.001
|
|
MON,(1 × 109/L)
|
0.4 (0.3–0.6)
|
0.4 (0.3–0.6)
|
0.4 (0.2–0.6)
|
0.205
|
|
PLT,(1 × 109/L)
|
178.0 (144.0–233.5)
|
186.0 (147.5–239.5)
|
153.0 (84.5–199.5)
|
< 0.001
|
|
HGB,(g/L)
|
129.0 (117.0–141.0)
|
130.0 (119.5–142.5)
|
117.0 (94.0–133.5)
|
< 0.001
|
|
FIB,(g/L)
|
4.1 (3.4–4.8)
|
4.1 (3.4–4.8)
|
3.9 (3.0–4.6)
|
0.340
|
|
IL-6,(pg/ml)
|
19.1 (7.7–42.8)
|
16.0 (7.1–33.8)
|
66.9 (22.6–112.5)
|
< 0.001
|
|
PCT,(ng/ml)
|
0.1 (0–0.2)
|
0.1 (0–0.1)
|
0.2 (0.1–0.4)
|
< 0.001
|
|
CRP,(mg/L)
|
25.2 (8.7–63.6)
|
20.1 (7.9–46.3)
|
70.0 (34.9–150.5)
|
< 0.001
|
|
ALT, (U/L)
|
24.0 (16.1–37.9)
|
24.0 (16.0–37.4)
|
25.8 (18.0–43.8)
|
0.378
|
|
TBIL, (umol/L)
|
11.3 (7.9–15.6)
|
10.9 (7.5–15.0)
|
13.3 (10.2–20.1)
|
0.004
|
|
DBIL, (umol/L)
|
3.7 (2.4–6.1)
|
3.5 (2.2–5.2)
|
5.8 (3.6–8.6)
|
< 0.001
|
|
CREA, (μmol/L)
|
65.0 (52.5–80.9)
|
64.0 (52.0–80.0)
|
68.4 (55.3–104.8)
|
0.096
|
|
Lac, (mmol/L)
|
1.6 (1.2–2.2)
|
1.5 (1.1–2.1)
|
1.9 (1.3–2.5)
|
0.077
|
|
Pa02/FiO2
|
237.9 (164.2–285.0)
|
247.3 (196.6–286.5)
|
143.3 (90.2–235.6)
|
< 0.001
|
